Pfizer Ramps Up Obesity, mRNA Flu and Skin-Drug Bets

Pfizer ( (PFE) ) has been popular among investors this week. Here is a recap of the key news on this stock.

Pfizer Inc. is quietly broadening its post-COVID growth story with fresh moves across obesity, vaccines, and dermatology. The company has begun dosing in a Phase 1 trial of PF-08653944, a subcutaneous weight management shot for adults with overweight or obesity, testing how the drug is absorbed when injected into the abdomen, thigh, or upper arm and tracking early safety signals.

While this early obesity data is unlikely to shift near-term earnings, it adds another option in a market dominated by Eli Lilly and Novo Nordisk and could support Pfizer’s long-range revenue mix if efficacy later proves competitive. In parallel, Pfizer is setting up a Phase 2, double-blind mRNA flu vaccine study in adults, pitting six experimental candidates against a standard flu shot as it seeks to build a durable mRNA franchise beyond COVID and challenge Moderna, Sanofi, and GSK.

The flu trial is still in the start-up phase and should be viewed as a multi-year program rather than an immediate catalyst for PFE shares, but strong immunogenicity data would help rebuild confidence in the company’s innovation engine. More immediately relevant for investors, Pfizer has completed its Phase 3 Tranquillo trial of ritlecitinib, an oral therapy for nonsegmental vitiligo, with 52-week data now under review and the study status updated to completed on February 25, 2026.

If ritlecitinib shows compelling skin repigmentation and safety, it could support regulatory filings in a visible dermatology indication and open a new revenue stream in immunology, potentially improving sentiment around PFE’s medium-term growth. Taken together, these three programs underscore Pfizer’s effort to diversify beyond its traditional vaccines and oncology base, with upcoming readouts and regulatory milestones poised to become key stock catalysts over the next several years.